Mycamine (Micafungin Sodium)

Micafungin sodium, the active ingredient in Mycamine, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive fungal infections, particularly candidiasis, and is used for prophylaxis in patients undergoing hematopoietic stem cell transplantation.\n\nGNH India supplies Mycamine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Mycamine (micafungin sodium) is an echinocandin antifungal used to treat and prevent serious Candida infections.\n\nInvasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.\nEsophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida species.\nProphylaxis in hematopoietic stem cell transplantation: prevents Candida infection in immunocompromised transplant recipients.

Micafungin sodium may be associated with a range of adverse reactions, varying from mild to severe.\n\nCommon Side Effects:\n- Elevated liver enzymes\n- Fever\n- Nausea\n- Headache\n- Infusion‑related reactions such as flushing or rash\n\nSerious or Rare Side Effects:\n- Severe hepatic dysfunction\n- Hypersensitivity reactions including anaphylaxis\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome)\n- Renal impairment\n- Cardiovascular events such as hypotension

When using Mycamine, clinicians should consider several safety measures.\n\nRenal function: monitor serum creatinine in patients with pre‑existing renal impairment.\nHepatic function: assess liver enzymes before and during therapy.\nDrug interactions: review concomitant medications that affect CYP enzymes.\nPregnancy and lactation: use only if potential benefit justifies potential risk.\nInfusion: administer under medical supervision; monitor for reactions.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inducers (e.g., rifampin) may markedly reduce micafungin exposure.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase micafungin levels and risk of toxicity.\n- Concurrent use with other echinocandins may increase the potential for additive toxicity.\n\nModerate Interactions (Monitor Closely):\n- Azole antifungals (e.g., fluconazole) may have additive antifungal effects.\n- Immunosuppressants such as tacrolimus may require dose adjustment.\n- Warfarin: monitor INR closely due to possible alteration of anticoagulant effect.